Tyler Stone Wealth Management grew its stake in Amgen Inc. (NASDAQ:AMGN – Free Report) by 160.6% in the third quarter, Holdings Channel.com reports. The institutional investor owned 959 shares of the medical research company’s stock after buying an additional 591 shares during the quarter. Tyler Stone Wealth Management’s holdings in Amgen were worth $309,000 as of its most recent SEC filing.
Several other large investors also recently made changes to their positions in AMGN. Baker Avenue Asset Management LP boosted its holdings in shares of Amgen by 107.2% during the 3rd quarter. Baker Avenue Asset Management LP now owns 3,212 shares of the medical research company’s stock worth $1,035,000 after buying an additional 1,662 shares during the period. Migdal Insurance & Financial Holdings Ltd. bought a new stake in Amgen during the third quarter valued at about $209,000. Sigma Planning Corp boosted its holdings in Amgen by 1.0% during the third quarter. Sigma Planning Corp now owns 18,633 shares of the medical research company’s stock valued at $6,004,000 after acquiring an additional 193 shares during the period. Arrow Financial Corp grew its position in shares of Amgen by 12.4% in the third quarter. Arrow Financial Corp now owns 14,688 shares of the medical research company’s stock valued at $4,733,000 after purchasing an additional 1,623 shares during the last quarter. Finally, Houlihan Financial Resource Group Ltd. increased its stake in shares of Amgen by 2.2% in the third quarter. Houlihan Financial Resource Group Ltd. now owns 3,506 shares of the medical research company’s stock worth $1,130,000 after purchasing an additional 77 shares during the period. Institutional investors own 76.50% of the company’s stock.
Amgen Stock Down 1.1 %
AMGN opened at $321.81 on Tuesday. Amgen Inc. has a twelve month low of $260.52 and a twelve month high of $346.85. The firm has a market cap of $172.98 billion, a price-to-earnings ratio of 41.20, a PEG ratio of 2.90 and a beta of 0.60. The firm’s 50-day simple moving average is $323.61 and its 200-day simple moving average is $317.70. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32.
Amgen Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be paid a $2.25 dividend. The ex-dividend date of this dividend is Monday, November 18th. This represents a $9.00 dividend on an annualized basis and a yield of 2.80%. Amgen’s payout ratio is presently 115.24%.
Wall Street Analyst Weigh In
A number of brokerages have recently commented on AMGN. Wells Fargo & Company lowered Amgen from an “overweight” rating to an “equal weight” rating and upped their price target for the stock from $320.00 to $335.00 in a report on Wednesday, August 7th. StockNews.com upgraded shares of Amgen from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Robert W. Baird restated an “underperform” rating and issued a $215.00 price target on shares of Amgen in a research report on Wednesday, September 25th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $362.00 price objective on shares of Amgen in a research report on Thursday, September 26th. Finally, Truist Financial downgraded Amgen from a “buy” rating to a “hold” rating and lifted their target price for the stock from $320.00 to $333.00 in a research report on Monday, October 14th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating, eleven have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $333.50.
View Our Latest Analysis on AMGN
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Featured Stories
- Five stocks we like better than Amgen
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- 2 Chip Stocks Benefitting from OpenAI’s Chip Strategy Expansion
- Are Penny Stocks a Good Fit for Your Portfolio?
- Monday.com’s Manic Price Pullback Is a Signal to Buy
- Are Penny Stocks a Good Fit for Your Portfolio?
- 3 “Made in America” Stocks to Benefit From the Trump Presidency
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.